Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jutta Miller"'
Autor:
Jun-Ho Jang, Raymond Wong, Jonathan Weyne, Umesh Chaudhari, Jutta Miller, Quang P. Nguyen, Morag Griffin
Publikováno v:
HemaSphere, Vol 7, p e4357016 (2023)
Externí odkaz:
https://doaj.org/article/6436c0cb73504c95acd92789166a1173
Autor:
Selin Somersan-Karakaya, Kenneth C. Turner, Luz Cortes-Burgos, Jutta Miller, Michael LaCroix-Fralish, Veronika Logovinsky, Yamini Patel, Richard Torres, Samit Ganguly, Aurora Breazna, Michelle DeVeaux, Rafia Bhore, Min Gao, Frank J. Delfino, Ashique Rafique, Jeanette L. Fairhurst, Charleen Hunt, Robert Babb, Ashok Badithe, William T. Poueymirou, Ronald Surowitz, Sylvie Rottey, Andrew J. Murphy, Olivier Harari, Lynn E. Macdonald, Susan D. Croll
Publikováno v:
Neurobiology of Pain, Vol 14, Iss , Pp 100136- (2023)
The artemin-GFRα3 signaling pathway has been implicated in various painful conditions including migraine, cold allodynia, hyperalgesia, inflammatory bone pain, and mouse knees contain GFRα3-immunoreactive nerve endings. We developed high affinity m
Externí odkaz:
https://doaj.org/article/c0682c375e514d369668aca491d09e17
Autor:
Jun Ho Jang, Raymond Wong, Jonathan Weyne, Umesh Chaudhari, Jutta Miller, Bradley Dain, Morag Griffin
Publikováno v:
Blood. 140:5309-5310
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6a49107e690eb61d2acaf4f459e7f6c
https://doi.org/10.1182/blood-2022-166627
https://doi.org/10.1182/blood-2022-166627
Autor:
Merideth L Rodgers, Lorah Perlee, Morton Lori C, David M. Weinreich, Oren Levy, Jonathan Weyne, Yiziying Chen, Olivier Harari, Tavé van Zyl, Karoline A Meagher, Jutta Miller, George D. Yancopoulos, Umesh Chaudhari
Publikováno v:
Blood. 138:1998-1998
Introduction. Pozelimab (REGN3918) and cemdisiran (ALN-CC5) are C5 inhibitors under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), myasthenia gravis (MG), and other diseases in which tissue damage is mediated by terminal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::232ef9439e1a12cf8d70e9ad6d6008c4
https://doi.org/10.1182/blood-2021-146205
https://doi.org/10.1182/blood-2021-146205
Autor:
Jonathan Weyne, David M. Weinreich, Jun-Ho Jang, Bradley Dain, Morag Griffin, Umesh Chaudhari, Morton Lori C, Merideth L Rodgers, Olivier Harari, Karoline A Meagher, Jutta Miller, George D. Yancopoulos, Lorah Perlee
Publikováno v:
Blood. 138:1128-1128
INTRODUCTION Paroxysmal Nocturnal hemoglobuinuria (PNH) is a rare, acquired, life-threatening disorder characterised by intravascular hemolysis and increased risk of thrombosis. Current available treatments represent a significant burden to patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5b859c2cc2e0fd82d25f19b615f4ed8
https://doi.org/10.1182/blood-2021-146178
https://doi.org/10.1182/blood-2021-146178
Autor:
Arthur J. Bergman, David Hreniuk, Maria Gutierrez, Lisa Hickey, Daniel M. Bloomfield, Kalyan Ghosh, Gary A. Herman, Rajesh Krishna, Randall Stoltz, Jutta Miller, John A. Wagner, Keith Gottesdiener
Publikováno v:
The Journal of Clinical Pharmacology. 49:937-946
A randomized, double-blind, placebo-controlled, 4-period crossover study was performed with a single oral dose of sitagliptin (100 mg, 800 mg), moxifloxacin (400 mg), and placebo in order to provide a rigorous assessment of the effect of sitagliptin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d1b9f7f1d0ddfefc9fd977ec2442361
https://doi.org/10.1177/0091270009337511
https://doi.org/10.1177/0091270009337511
Autor:
Marian Iwamoto, Thomas N. Kakuda, Julie A. Stone, William D. Hanley, Larissa Wenning, James Kost, John A. Wagner, Randall Stoltz, Jutta Miller, Matt S. Anderson, Richard M. W. Hoetelmans
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:4228-4232
Etravirine, a next-generation nonnucleoside reverse transcriptase inhibitor, and raltegravir, an integrase strand transfer inhibitor, have separately demonstrated potent activity in treatment-experienced, human immunodeficiency virus (HIV)-infected p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff514cbf93d4f6ccae2af65a29c6cdb
https://doi.org/10.1128/aac.00487-08
https://doi.org/10.1128/aac.00487-08
Autor:
Deborah Hilliard, Jules I. Schwartz, Derek L Chappell, Karen Snyder, Omar F Laterza, Patrick Larson, Jutta Miller, Mary Flynn, John A. Wagner, Jane Royalty, Aimee Dallob, Paul F. Cavanaugh
Publikováno v:
The Journal of Clinical Pharmacology. 48:745-754
We determined cyclo-oxygenase-1 and cyclo-oxygenase-2 inhibition in healthy middle-aged subjects (41-65 years) randomly assigned to four 7-day treatment sequences of etoricoxib 90 mg every day, celecoxib 200 mg twice a day, diclofenac 75 mg twice a d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5cb6ad034ecc121a79249ee904f1db4
https://doi.org/10.1177/0091270008317590
https://doi.org/10.1177/0091270008317590
Autor:
Kenneth C. Lasseter, David Hreniuk, Barry J. Gertz, Deborah Hilliard, Chau Thach, Jutta Miller, Jules I. Schwartz, Keith Gottesdiener, Karen Snyder
Publikováno v:
The Journal of Clinical Pharmacology. 47:1521-1531
This multicenter, double-blind, randomized, placebo-controlled, parallel-group study assessed renal function during dosing with etoricoxib 90 mg daily, celecoxib 200 mg twice daily, and naproxen 500 mg twice daily. Male and female subjects 60 to 81 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c84996274e4f98ffcce89ecdc932784
https://doi.org/10.1177/0091270007307878
https://doi.org/10.1177/0091270007307878
Autor:
Marina De Smet, Haiyuan Zhu, Zissi Matthijs, Katelijn Decochez, Hengchang Song, Amy O. Johnson-Levonas, Hannah O Maynor, Ronda K. Rippley, Jutta Miller, Kerri X. Yan, John A. Wagner, Bart Keymeulen, Keith Gottesdiener, Michael J. Davies, Kerry Riffel, Wesley Tanaka
Publikováno v:
Drugs in R & D. 7:99-110
Background: The objective of these studies was to evaluate the pharmacokinetics and pharmacodynamics of MK-0767, a prototypical dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist, following administration of single and multiple oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::953c7f84811c4be8d08b56ccde70484e
https://doi.org/10.2165/00126839-200607020-00004
https://doi.org/10.2165/00126839-200607020-00004